Загрузка...
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
BACKGROUND: Therapeutic antibodies targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis induce potent and durable anti-tumor responses in multiple types of cancers. However, only a subset of patients benefits from anti-PD-1/PD-L1 therapies. As a negative regulator...
Сохранить в:
| Опубликовано в: : | J Hematol Oncol |
|---|---|
| Главные авторы: | , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7885589/ https://ncbi.nlm.nih.gov/pubmed/33593403 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-021-01045-x |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|